|
|
 |
|
Viewing report
|
|
|
|
U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
Frost & Sullivan, May 2011, Pages: 72
This research service covers the U.S. rheumatoid arthritis (RA) market from 2007 to 2017, with 2010 as the base year. Included in this research service are products currently in the market, products in development, and patient forecasts. Market challenges, drivers, and restraints are identified and assessed. Strategic recommendations are presented to overcome listed industry challenges. This research service does not include market revenue forecasts for DMARDs. This research service highlights product forecasts for biologic products as well as small molecules near launch.
Research Overview
This Frost & Sullivan research service titled U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments provides an overview of industry trends and revenue forecasts. It also provides a complete analysis of key drivers and restraints as well as challenges that affect the rheumatoid arthritis (RA) market. Market trends have been evaluated following extensive interviews with market participants. In this research, Frost & Sullivan's expert analysts thoroughly examine the following drug classes: disease-modifying antirheumatic drugs (DMARDs), anti-tumor necrosis factor alpha (anti-TNF-alphas), other biologics, and small molecules.
Market Overview
Increase in Incidence of RA from 2.4 million in 2010 to 2.6 million in 2017 Encourage Development of New Drugs
High Unmet Need for Safe Treatment to Expand the Pipeline for RA Drugs
Owing to the unmet need for a convenient and safe RA treatment option without adverse side effects, a spate of new drug launches in the near future is imminent. As a result of this demand, some of the current pipeline drugs have the potential to be blockbusters, especially the oral treatments in late-stage development. In 2010, the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) revised the 1987 classification criteria for RA to enable early detection. The new classification facilitates diagnosing RA patients and thereby, gives a boost to the treatment market. The first line of biologic agents, after methotrexate, are Enbrel and Humira; Remicade, Simponi, and Cimzia are additional anti-TNF options. If patients experience TNF failure, physicians then will either change to a second anti-TNF or switch classes to Orencia, Actemra, or Rituxan. Compounds in the late stages of development include CP-690,550 and fostamatinib disodium. CP-690,550 (tasocitinib) is a Janus kinases (JAK) 1/3 inhibitor, which is expected to be the first oral compound to reach the RA market for DMARDs inadequate responders (IR). As tasocitinib is being developed as an oral medication, it has the potential to be used ahead of TNF antagonists in the RA treatment paradigm. R788 is also being evaluated as an oral twice-a-day treatment, as it can be an improvement on the expensive TNF blockers that are delivered subcutaneously or intravenously and have side effects.
Small molecules such as Pfizer’s CP-690,550 can have a big impact on the market, if they demonstrate positive safety and efficacy data due to the convenience and low cost of oral therapy. “With the number of biologics on the market and in development for RA, the RA treatment market is becoming crowded,” says the analyst of this research. “Biologics entering this market must be able to show efficacy and safety data that is comparable, if not superior, to TNF blockers to gain any market share.” Currently, many biologics such as TNF antagonists are associated with severe adverse events such as infections and lymphoma. Safety concerns and the annual cost of RA treatment, which can vary from $10,000 to $20,000, can restrain patients - especially uninsured ones - from opting for biologics.
With the patent of the first-line biologic - Enbrel - due to expire in 2012, the entry of biosimilars could be a game changer. Although they can increase adoption rates and availability, these low-priced generics could reduce revenue generation rates. If adequate reimbursements are not available, patients may choose biosimilars over expensive novel therapies, which will slow down the market’s growth rate. Tight budgets from insurance companies will further restrict the use of novel therapies and encourage generics. “Biosimilars are expected to influence the U.S. market in the next three to four years,” notes the analyst. “To fight back the challenge from these generics, pharmaceutical and biotech companies need to continue to address unmet needs in the treatment of RA by developing novel medications.”
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
By Drug Class:
- Disease-modifying antirheumatic drugs (DMARDs)
- Anti-tumor necrosis factor alpha (anti-TNF-alphas)
- Other biologics
- Small molecules
Technologies
The following technologies are covered in this research:
- Subcutaneous injection
- Intravenous infusion
- Oral administration
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
